Merck to buy Verona for $10 billion ahead of Keytruda patent expiration

We've been talking about Merc all morning long. We were just talking about M&A in fact as well. So the company's buying Verona Pharma for about $10 billion as it looks to diversify uh its portfolio beyond Kitruda.That's a tough one to be facing patent expirations. That's a a huge drug and a great drug. Angelica Peoples joins us on set with a look uh at the big M&A theme emerging uh from the industry.Good morning. Morning Joe. That's right.And like you mentioned for Merc, they have about a $30 billion hole t ...